The efficacy and toxicity of angiogenesis inhibitors for ovarian cancer: a meta-analysis of randomized controlled trials

被引：0
|
作者：
Chongzhen Guo
Chengda Yan
Lianyue Qu
Rongrong Du
Jianyang Lin
机构：
[1] The First Hospital of China Medical University,Department of Pharmacy
[2] China Medical University,School of Pharmaceutical Science
来源：
Archives of Gynecology and Obstetrics | 2021年 / 303卷
关键词：
Angiogenesis inhibitors; Ovarian cancer; Progression-free survival; Overall survival; Toxicity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：285 / 311
页数：26
相关论文
共 50 条
  • [31] Antiangiogenesis therapy in ovarian cancer patients An updated meta-analysis for 15 randomized controlled trials
    Jiang, Yanyan
    Sun, Xiaomei
    Kong, Beihua
    Jiang, Jie
    MEDICINE, 2018, 97 (34)
  • [32] Tyrosine kinase inhibitors for advanced or metastatic thyroid cancer: a meta-analysis of randomized controlled trials
    Liu, Jen-Wei
    Chen, Chiehfeng
    Loh, El-Wui
    Chu, Chun-Cheng
    Wang, Mu-Yi
    Ouyang, Hsin-Ju
    Chang, Ya-Ting
    Zhuang, Wei-Zhan
    Chou, Ching-Wen
    Huang, Der-Jr
    Lee, Chia-Hwa
    Yen, Yun
    Tam, Ka-Wai
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (05) : 795 - 803
  • [33] Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials
    Marchetti, Claudia
    De Felice, Francesca
    Palaia, Innocenza
    Musella, Angela
    Di Donato, Violante
    Gasparri, Maria Luisa
    Musio, Daniela
    Muzii, Ludovico
    Tombolini, Vincenzo
    Panici, Pierluigi Benedetti
    ONCOTARGET, 2016, 7 (11) : 13221 - 13227
  • [34] Efficacy and Safety of PARP Inhibitor Therapy in Advanced Ovarian Cancer: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials
    Chen, Juying
    Wu, Xiaozhe
    Wang, Hongzhe
    Lian, Xiaoshan
    Li, Bing
    Zhan, Xiangbo
    CURRENT COMPUTER-AIDED DRUG DESIGN, 2024, 20 (06) : 736 - 751
  • [35] Efficacy and safety of PARP inhibitors combined with antiangiogenic agents in the maintenance treatment of ovarian cancer: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials
    Wei, Yan
    He, Li
    Liu, Tao
    Guo, Tao
    Xie, Cong
    Jia, Jigang
    Lin, Yonghong
    Liu, Jiang
    Fan, Jiayin
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [36] The Role of Pegylated Liposomal Doxorubicin in Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials
    Gibson, Jean-Marie
    Alzghari, Saeed
    Ahn, Chul
    Trantham, Holly
    La-Beck, Ninh M.
    ONCOLOGIST, 2013, 18 (09) : 1022 - 1031
  • [37] Efficacy and safety of olaparib in advanced ovarian cancer: a meta-analysis
    Yang, Yuanyuan
    Yang, Xiaoyun
    Li, Huaifang
    Tong, Xiaowen
    Zhu, Xinxian
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2023, 43 (01)
  • [38] Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials
    Ruscito, Ilary
    Bellati, Filippo
    Ray-Coquard, Isabelle
    Mirza, Mansoor Raza
    du Bois, Andreas
    Gasparri, Maria Luisa
    Costanzi, Flavia
    De Marco, Maria Paola
    Nuti, Marianna
    Caserta, Donatella
    Pignata, Sandro
    Dorigo, Oliver
    Sehouli, Jalid
    Braicu, Elena Ioana
    CANCER TREATMENT REVIEWS, 2020, 87
  • [39] Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in the treatment of advanced thyroid cancer: a meta-analysis of randomized controlled trials
    Yimaer, Wufuer
    Abudouyimu, Aizizi
    Tian, Ye
    Magaoweiya, Sailike
    Bagedati, Duman
    Wen, Hao
    ONCOTARGETS AND THERAPY, 2016, 9 : 1167 - 1173
  • [40] Bevacizumab in the treatment of ovarian cancer: a meta-analysis from four phase III randomized controlled trials
    Qing Ye
    Hong-Lin Chen
    Archives of Gynecology and Obstetrics, 2013, 288 : 655 - 666
12345